125 related articles for article (PubMed ID: 24472718)
1. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis.
Caldarella C; Treglia G; Giordano A
Clin Breast Cancer; 2014 Aug; 14(4):241-8. PubMed ID: 24472718
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
[TBL] [Abstract][Full Text] [Related]
3. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.
Berg WA; Weinberg IN; Narayanan D; Lobrano ME; Ross E; Amodei L; Tafra L; Adler LP; Uddo J; Stein W; Levine EA;
Breast J; 2006; 12(4):309-23. PubMed ID: 16848840
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer.
Berg WA; Madsen KS; Schilling K; Tartar M; Pisano ED; Larsen LH; Narayanan D; Kalinyak JE
AJR Am J Roentgenol; 2012 Jan; 198(1):219-32. PubMed ID: 22194501
[TBL] [Abstract][Full Text] [Related]
5. Can 18F-FDG PET improve the evaluation of suspicious breast lesions on MRI?
Bitencourt AG; Lima EN; Chojniak R; Marques EF; Souza JA; Andrade WP; Guimarães MD
Eur J Radiol; 2014 Aug; 83(8):1381-6. PubMed ID: 24931922
[TBL] [Abstract][Full Text] [Related]
6. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
9.
Watanabe G; Itoh M; Duan X; Watabe H; Mori N; Tada H; Suzuki A; Miyashita M; Ohuchi N; Ishida T
Eur Radiol; 2018 May; 28(5):1929-1937. PubMed ID: 29218614
[TBL] [Abstract][Full Text] [Related]
10. Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography?
Bitencourt AG; Lima EN; Macedo BR; Conrado JL; Marques EF; Chojniak R
Eur Radiol; 2017 May; 27(5):1893-1900. PubMed ID: 27585658
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Detection Using a Low-Dose Positron Emission Digital Mammography System.
Freitas V; Li X; Scaranelo A; Au F; Kulkarni S; Ghai S; Taeb S; Bubon O; Baldassi B; Komarov B; Parker S; Macsemchuk CA; Waterston M; Olsen KO; Reznik A
Radiol Imaging Cancer; 2024 Mar; 6(2):e230020. PubMed ID: 38334470
[TBL] [Abstract][Full Text] [Related]
12. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging.
Schilling K; Narayanan D; Kalinyak JE; The J; Velasquez MV; Kahn S; Saady M; Mahal R; Chrystal L
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):23-36. PubMed ID: 20871992
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy.
Uematsu T; Kasami M; Yuen S
Breast Cancer; 2009; 16(2):97-104. PubMed ID: 18663562
[TBL] [Abstract][Full Text] [Related]
15. The current status of positron emission mammography in breast cancer diagnosis.
Kalles V; Zografos GC; Provatopoulou X; Koulocheri D; Gounaris A
Breast Cancer; 2013 Apr; 20(2):123-30. PubMed ID: 23239242
[TBL] [Abstract][Full Text] [Related]
16. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG.
Murthy K; Aznar M; Thompson CJ; Loutfi A; Lisbona R; Gagnon JH
J Nucl Med; 2000 Nov; 41(11):1851-8. PubMed ID: 11079494
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
18. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast.
Berg WA; Madsen KS; Schilling K; Tartar M; Pisano ED; Larsen LH; Narayanan D; Ozonoff A; Miller JP; Kalinyak JE
Radiology; 2011 Jan; 258(1):59-72. PubMed ID: 21076089
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.
Isasi CR; Moadel RM; Blaufox MD
Breast Cancer Res Treat; 2005 Mar; 90(2):105-12. PubMed ID: 15803356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
